HCPCS Level II · Drugs administered other than oral method
J1655Injection, tinzaparin sodium, 1000 iu
Terminated 12/31/2025
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J1655
J1655 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing injection, tinzaparin sodium, 1000 iu.
It was added to HCPCS effective 01/01/2002, and its current record took effect 01/01/2026.
It was terminated on 12/31/2025 and can't be billed for later dates of service.
Its Medicare coverage code is "C", meaning coverage is left to the Medicare contractor's judgment.
Details
- Short description
- Tinzaparin sodium injection
- Date added
- 01/01/2002
- Action effective
- 01/01/2026
- Termination date
- 12/31/2025
- BETOS
- O1E
Related J16xx codes
- J1600Injection, gold sodium thiomalate, up to 50 mg
- J1602Injection, golimumab, 1 mg, for intravenous use
- J1610Injection, glucagon hydrochloride, per 1 mg
- J1611Injection, glucagon hydrochloride (fresenius kabi), not therapeutically equivalent to j1610, per 1 mg
- J1612Injection, glucagon (gvoke), 0.01 mg
- J1626Injection, granisetron hydrochloride, 100 mcg
- J1627Injection, granisetron, extended-release, 0.1 mg
- J1628Injection, guselkumab, 1 mg
- J1630Injection, haloperidol, up to 5 mg
- J1631Injection, haloperidol decanoate, per 50 mg
- J1632Injection, brexanolone, 1 mg
- J1640Injection, hemin, 1 mg
Common questions about J1655
Is HCPCS J1655 still valid?
- No. J1655 was terminated on 12/31/2025.
Does Medicare cover J1655?
- Its coverage code is "C": coverage is left to the Medicare contractor's judgment. Check the local coverage determination for your region.